MSB 3.78% $1.08 mesoblast limited

Apart from the fact that you are making inherently...

  1. 30,333 Posts.
    lightbulb Created with Sketch. 1837
    Apart from the fact that you are making inherently unsubstantiated comments,

    you haven't


    - made any demonstrable progress whatsoever into understanding why the MSB technology makes the commercialisation such a game changer, and to understand commercial risk/reward you have to understand that.

    - gone into the MSB website and investigated the background and links (no demonstrable evidence)


    - commented on the links I recently posted in which an expert in the area explained that Australian analysis of companies with patents as their key assets, is so deficient (tricky grammar there)

    - explained why you keep hanging around this stock simply to deride it's SP, or make vague noises about risk which are never quantified never analysed, just vague

    - got a consistent back story. One minute a mum & dad investor, the next you've got a Bloomberg terminal, the next you're confiding that you're a retired broker/investor with 25 years experience. Next you're a hardscrabble mining toughie with an improbably excellent grasp of grammar....somewhere in all of that, the claim that you're sponsoring research into how shorted biotechs are a very good indicator of value has disappeared.

    (you're one of the wiliest posters I've yet encountered in here,...inviting insults like you're slow?...pretending you haven't noticed that traders with runs on the competition board are following you? please...keep it real.)

    So your focus is on risk?

    Really? How about telling us what you've actually discovered about MSB for a change?

    You tell us why the ability to upscale commercial production of stem cells that do not present a problem with rejection in the recipient, and are demonstrated to work, is a much greater risk than an opportunity?

    You tell us why the JV agreement with a major pharma is an albatross around your neck and not a huge plus by financing our clinical trials...a unique situation for a biotech.

    Because if you're solely worried about risk, you don't understand reward.

    Something is not right about your claims.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.08
Change
-0.043(3.78%)
Mkt cap ! $1.255B
Open High Low Value Volume
$1.14 $1.16 $1.08 $6.043M 5.462M

Buyers (Bids)

No. Vol. Price($)
39 427166 $1.08
 

Sellers (Offers)

Price($) Vol. No.
$1.09 31440 17
View Market Depth
Last trade - 15.13pm 29/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.